Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression | Zendy

Minehiko Inomata | Zendy; Naoki Takata | Zendy; Isami Mizushima | Zendy; Kenji Azechi | Zendy; Kana Hayashi | Zendy; Kotaro Tokui | Zendy; Chihiro Taka | Zendy; Seisuke Okazawa | Zendy; Kenta Kambara | Zendy; Shingo Imanishi | Zendy; Toshiro Miwa | Zendy; Ryuji Hayashi | Zendy; Shoko Matsui | Zendy; Kazuyuki Tobe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression

Author(s) -

Minehiko Inomata,

Naoki Takata,

Isami Mizushima,

Kenji Azechi,

Kana Hayashi,

Kotaro Tokui,

Chihiro Taka,

Seisuke Okazawa,

Kenta Kambara,

Shingo Imanishi,

Toshiro Miwa,

Ryuji Hayashi,

Shoko Matsui,

Kazuyuki Tobe

Publication year - 2021

Publication title -

cancer diagnosis and prognosis

Language(s) - English

Resource type - Journals

ISSN - 2732-7787

DOI - 10.21873/cdp.10023

Subject(s) - medicine , lung cancer , oncology , proportional hazards model , cancer , pd l1 , immunotherapy , immune system , immune checkpoint , retrospective cohort study , tumor progression , metastasis , immunology

We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research